[{"address1": "4660 La Jolla Village Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "650 800 3717", "website": "https://www.revbiosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Rolke", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 649250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chester Stanley Zygmont III", "age": 43, "title": "CFO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 479141, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Vedrick", "title": "Vice President of Human Resources & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carol  Odle", "title": "Senior Director of Clinical Projects", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.74, "open": 2.71, "dayLow": 2.595, "dayHigh": 2.77, "regularMarketPreviousClose": 2.74, "regularMarketOpen": 2.71, "regularMarketDayLow": 2.595, "regularMarketDayHigh": 2.77, "beta": 0.15, "forwardPE": -0.1409645, "volume": 33488, "regularMarketVolume": 33488, "averageVolume": 403593, "averageVolume10days": 87816, "averageDailyVolume10Day": 87816, "marketCap": 4343620, "fiftyTwoWeekLow": 2.22, "fiftyTwoWeekHigh": 49.8, "fiftyDayAverage": 3.93264, "twoHundredDayAverage": 16.16787, "currency": "USD", "enterpriseValue": -7648094, "floatShares": 1626795, "sharesOutstanding": 1632940, "sharesShort": 32782, "sharesShortPriorMonth": 36087, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.08270001, "heldPercentInsiders": 0.00324, "heldPercentInstitutions": 0.01963, "shortRatio": 0.09, "shortPercentOfFloat": 0.0833, "impliedSharesOutstanding": 1632940, "bookValue": 25.13, "priceToBook": 0.10584959, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -120254, "trailingEps": -0.53, "forwardEps": -18.87, "lastSplitFactor": "1:30", "lastSplitDate": 1706140800, "enterpriseToEbitda": 0.886, "52WeekChange": -0.93141025, "SandP52WeekChange": 0.28136122, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "REVB", "underlyingSymbol": "REVB", "shortName": "Revelation Biosciences, Inc.", "longName": "Revelation Biosciences, Inc.", "firstTradeDateEpochUtc": 1641911400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f994477e-3690-3dde-965e-6f9faa0f03d6", "messageBoardId": "finmb_696222591", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.66, "targetHighPrice": 39.25, "targetLowPrice": 25.0, "targetMeanPrice": 32.13, "targetMedianPrice": 32.13, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 11991701, "totalCashPerShare": 7.344, "ebitda": -8631615, "quickRatio": 2.155, "currentRatio": 2.183, "returnOnAssets": -0.61079, "returnOnEquity": -0.031229999, "freeCashflow": -4111234, "operatingCashflow": -7286286, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]